Skip to content
MARKETS / NASDAQ / AUTL
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Autolus Therapeutics PLC AUTL

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$75.4M
▲ 644.9% YoY
$-287.5M
$-302.6M
In brief

What this company does

In November 2024, the FDA approved the company's biologics license application for AUCATZYL for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. In addition to AUCATZYL/obe-cel for adult r/r B-ALL, the company is advancing obe-cel in other oncology indications including pediatric B-ALL and B-NHL. As of December 31, 2025, the company had 752 full-time employees, 113 of whom hold Ph.D. or M.D. degrees. The company is a public limited company, originally incorporated under the laws of England and Wales in February 2018 as a private company with limited liability called Autolus Therapeutics Limited. On June 18, 2018, Autolus Therapeutics Limited re-registered as a public limited company and was renamed Autolus Therapeutics plc.

Written from the business description in Autolus Therapeutics plc's annual report to the U.S. Securities and Exchange Commission, filed 27 March 2026. Every sentence was checked against that document before publication.

Growth
USD 75.4M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 75.4 · Net income -287.5
40M-100M-200M2016201720182019202020212022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−381 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -358.9% · Net -381.4%
-5000%-10000%2016201720182019202020212022202320242025
ROE
FY2025 · ROE -95.0%
-50%-100%2016201720182019202020212022202320242025

Each USD of equity lost 95 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -302.6
-200M2016201720182019202020212022202320242025

Total assetsUSD 589.1M
EquityUSD 178.1M
CashUSD 104.1M
Current ratio5.94×

Equity funds 30% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.10.00.0···0.00.00.00.0
Operating income $B−0.3−0.2−0.2−0.1−0.1−0.2−0.1−0.1−0.0−0.0
EBITDA $B−0.3−0.2−0.2−0.1−0.1−0.2−0.1−0.1−0.0−0.0
Income tax $B0.00.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.3−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.3−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−1.08−0.86−1.20−1.57−1.97−2.76−2.88−1.42−1.43−1.26
Dividend / sh $··········
Payout %··········
ROE %−95.0−81.9−101.6−48.6−54.3−61.1−48.5−22.5−22.8−40.9

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 38 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 54 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image